{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=18",
    "query": {
      "condition": "Hepatitis C Virus Infection",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 901,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Infection&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T14:30:38.292Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02114177",
      "title": "Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "Simeprevir",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Infectious Diseases BVBA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 310,
      "start_date": "2014-04",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-12",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 38,
      "location_summary": "Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02114177"
    },
    {
      "nct_id": "NCT00189163",
      "title": "Pioglitazone in Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2005-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00189163"
    },
    {
      "nct_id": "NCT00314054",
      "title": "Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C",
        "Hepatic Insufficiency"
      ],
      "interventions": [
        {
          "name": "HCV-796",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 27,
      "start_date": "2006-05",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2008-04-14",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Orlando, Florida • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00314054"
    },
    {
      "nct_id": "NCT00655226",
      "title": "Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C",
        "Depressive Disorder, Major",
        "Depressive Disorder",
        "Depression",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Hepatitis C educational support groups",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Behavioral Therapy skills based group sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2008-03",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2011-08-09",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655226"
    },
    {
      "nct_id": "NCT01241760",
      "title": "VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Genotype 1 Chronic Hepatitis C",
        "Treatment Naive"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Infectious Diseases BVBA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 744,
      "start_date": "2010-12",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 37,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 34 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01241760"
    },
    {
      "nct_id": "NCT00001117",
      "title": "A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections",
        "Hepatitis C"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 60,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-08-01",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 42,
      "location_summary": "Los Angeles, California • Menlo Park, California • San Diego, California + 27 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Menlo Park",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Rafael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001117"
    },
    {
      "nct_id": "NCT00249574",
      "title": "Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C",
        "Heroin Dependence"
      ],
      "interventions": [
        {
          "name": "Buprenorphine/naloxone",
          "type": "DRUG"
        },
        {
          "name": "pegInterferon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2003-06",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-16",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00249574"
    },
    {
      "nct_id": "NCT02597790",
      "title": "A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Hepatitis C"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2013-10",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2022-01-20",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02597790"
    },
    {
      "nct_id": "NCT01356160",
      "title": "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "GS-5885",
          "type": "DRUG"
        },
        {
          "name": "GS-9451",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ribavirin tablet",
          "type": "DRUG"
        },
        {
          "name": "GS-9451 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 351,
      "start_date": "2011-07",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2014-02-03",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 21,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01356160"
    },
    {
      "nct_id": "NCT00001035",
      "title": "The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Interferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Zalcitabine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 10,
      "start_date": null,
      "completion_date": "1996-09",
      "has_results": false,
      "last_update_posted_date": "2012-04-30",
      "last_synced_at": "2026-10-14T14:30:38.292Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Indianapolis, Indiana • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001035"
    }
  ]
}